Literature Highlights

Each month the Steering Committee selects the latest published original articles on immune-mediated inflammatory diseases, focusing on those with data on therapeutic interventions and those that have clinical impact.

November 2024

PsA Literature Highlights - November 2024

more…

Keywords:

Bimekizumab, Phase 3, PRO/QoL, Real-World,

RA Literature Highlights - November 2024

more…

Keywords:

ACR, Adalimumab, Efficacy, Filgotinib, Infections, JAK, MTX, Tofacitinib

October 2024

IBD Literature Highlights - October 2024

more…

Keywords:

Efficacy, Phase 3, Remission, Risankizumab, Safety

Psoriasis Literature Highlights - October 2024

more…

Keywords:

Bimekizumab, Efficacy, Outcomes, Safety

AxSpA Literature Highlights - October 2024

more…

Keywords:

IL-17, Ixekizumab, Real-World, Secukinumab, TNF, Tofacitinib

PsA Literature Highlights - October 2024

more…

Keywords:

Efficacy, IL-23, IL-17, Secukinumab, Safety

RA Literature Highlights - October 2024

more…

Keywords:

Baricitinib, DMARDs, Disease activity, Difficult-to-treat, Efficacy, JAK inhibitors, Meta-analysis, Network Meta-Analysis, Randomized controlled trials, Rheumatoid arthritis, Safety, Systemic review, TNF inhibitors,

September 2024

IBD Literature Highlights - September 2024

more…

Keywords:

Efficacy, IL-23, Phase 3, Remission, Safety

Psoriasis Literature Highlights - September 2024

more…

Keywords:

Efficacy, IL-23, Outcomes, Safety

AxSpA Literature Highlights - September 2024

more…

Keywords:

Persistence, Secukinumab, Efficacy, Safety, JAK